ArticleScientific reports2025
Left ventricular global longitudinal strain and diagnostic yield of genetic testing in hypertrophic cardiomyopathy in a multicenter registry analysis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Complication management in hypertrophic cardiomyopathy.Heart failure reviews · 2026Review
- The prospective Austrian hypertrophic cardiomyopathy registry - design, methods and results of the run-in period.Heart failure reviews · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
In this multicenter study we investigated whether echocardiography-derived left ventricular global longitudinal strain (LV GLS), an indicator of myocardial fibrosis, independently predicts a positive genotype in hypertrophic cardiomyopathy (HCM). We performed a cross-sectional analysis including HCM patients with genetic testing results and echocardiographic data from two Austrian HCM registries. Echocardiographic parameters were measured in post-processing analysis by a blinded investigator. Among 125 patients with HCM, a positive genotype was present in 39%. Worse LV GLS was associated with a positive genotype in univariate analysis (Odds Ratio [OR] 95% CI 1.141, 1.018-1.279, p = 0.023). In multivariate regression analysis adjusted for genotype predictors (age at diagnosis < 45 years, arterial hypertension, positive family history of HCM, maximal to posterior wall thickness [MWTH: PWTH], reverse curve septal phenotype), the reverse curve septal phenotype remained as a single independent predictor of genotype-positive HCM (OR 6.948, 2.342-20.614, p < 0.001). Adding LV GLS to established Toronto and Mayo genotype prediction scores did not improve their performance. To conclude, worse LV GLS was not independently associated with genotype-positive HCM and did not improve the diagnostic yield of genetic testing in HCM in a multivariate model. Our study highlights the reverse curve septal phenotype as the strongest genotype predictor in HCM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.